BURLINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place April 8-9, 2014, at The Westin New York Grand Central.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
CONTACT: Media Contact
Jamie Lacey-Moreira
PressComm PR, LLC
T: 410-299-3310
jamielacey@presscommpr.com
Corporate Contact
Lisa Davidson, MBA
Vice President, Finance and Administration
Flexion Therapeutics
T: 781-305-7765
ldavidson@flexiontherapeutics.com
